Core Viewpoint - The inclusion of Naxitamab in the commercial insurance directory is a significant advancement for children suffering from rare diseases, showcasing the successful implementation of the Boao Lecheng policy by Guangzhou Pharmaceutical Morning Fei [3]. Group 1: Company Achievements - Guangzhou Pharmaceutical Morning Fei has successfully introduced nearly 30 innovative imported drugs and medical devices, most of which have been transformed for domestic use, bridging international products with local healthcare needs [4]. - The company has facilitated early access to Naxitamab, allowing patients to receive the drug 18 months ahead of its official domestic launch, with prices being only one-seventh of those in the United States [3][4]. Group 2: Policy Impact - The Boao Lecheng pilot policy has created a green channel for patients in China, enabling early and cost-effective access to foreign medications, particularly for rare diseases, which are a national focus due to their high development costs and pricing [4]. - The support from national commercial insurance significantly reduces the financial burden on families, making essential medications more affordable [4]. Group 3: Future Plans - The company plans to leverage zero tariffs and streamlined administrative processes under the free trade port policy to expand the introduction of quality drugs and medical devices, aiming to provide affordable medications for more patients with rare and severe diseases without the need to go abroad [5].

Core Viewpoint - The implementation of the new national basic medical insurance drug list and the first commercial health insurance innovative drug list in Beijing on January 1, 2026, introduces 114 new drugs into the basic insurance reimbursement scope and 19 innovative drugs into the commercial insurance list, significantly benefiting patients [1][2]. Group 1: New Drug Inclusion - The new national medical insurance directory includes a total of 3,253 drugs, with 114 new drugs added, covering critical treatment areas such as cancer, chronic diseases, and rare diseases [1]. - Notable new drugs include the anti-cancer drug Lurbinectedin for triple-negative breast cancer, the diabetes medication Tirzepatide, and treatments for rare diseases like Langerhans cell histiocytosis [1]. Group 2: Commercial Insurance Drug List - The commercial insurance list includes 19 innovative drugs, focusing on high innovation, significant clinical value, and substantial patient benefits beyond the basic insurance coverage [1]. - Included innovative treatments are CAR-T cell immunotherapy products, biological agents for Alzheimer's disease, and specific drugs for Gaucher disease and short bowel syndrome [1]. Group 3: Patient Impact - An 8-year-old boy with high-risk neuroblastoma became one of the first beneficiaries of the new policy, with his treatment costs significantly reduced from tens of thousands of yuan annually to being partially covered by commercial insurance [2]. - The inclusion of GD2 antibody therapy in the commercial insurance list allows families to shift from full out-of-pocket expenses to insurance reimbursement, alleviating financial burdens [2]. Group 4: Transition Period and Adjustments - A 6-month transition period is established for drugs removed from the old national medical insurance directory, allowing them to still be reimbursed until June 30, 2026 [3]. - The Beijing Medical Insurance Bureau has mandated timely adjustments in drug supply at medical institutions and updates to the insurance information system to ensure patient access to necessary medications [3].